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Abstract
Asthma in the elderly (.65 yr old) is common and associated with
highermorbidity andmortality than asthma in younger patients. The
poor outcomes in this group are due, in part, to underdiagnosis and
undertreatment.Thereareavarietyof factorsrelatedtoagingitself thataffect
the presentation of asthma in the elderly and inﬂuence diagnosis and
management. Structural changes in the aging lung superimposed on
structural changes due to asthma itself can worsen the disease and
physiologic function. Changes in the aging immune system inﬂuence the
cellularcompositionandfunctioninasthmaticairways.Theseprocessesand
differences from younger individuals with asthma are not well understood.
Phenotypesofasthmain theelderlyhavenotbeenclearlydelineated,but it is
likely that age of onset and overlap with chronic obstructive pulmonary
disease impactdisease characteristics.Physiologic tests andbiomarkersused
todiagnoseandfollowasthmaintheelderlyaregenerallysimilar totesting in
younger individuals;however,whether theyshouldbemodiﬁed inaginghas
not been established. Confounding inﬂuences, such as comorbidities
(increasing the risk of polypharmacy), impaired cognition andmotor skills,
psychosocial effects of aging, and age-related adverse effects ofmedications,
impact bothdiagnosis and treatment of asthma in the elderly. Future efforts
to understand asthma in the elderly must include geriatric-speciﬁc
methodology to diagnose, characterize, monitor, and treat their disease.
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Overview
There are now more Americans over
the age of 65 years than at any other time in
United States history, and their numbers
increased 15.1% in the past decade (1).
In 2014, 14% of the U.S. population was older
than 65 years, and in other countries this
number was considerably higher (2). The
U.S. aging population is expected to increase
rapidly over the next decade. Active asthma is
common in patients older than 65 years of
age and can be severe and disabling, with
marked ventilatory impairment (3–5) and
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negative impact on quality of life (QOL) (6).
Asthma in older patients may persist from
childhood or may begin in adulthood, even
at an advanced age. Across the American
lifespan, those who were 65 years and older
had the largest increase in the prevalence of
current asthma, from 6.0% in 2001 to 8.1% in
2010 (7). Importantly, this age group had the
highest rate of asthma deaths and asthma-
based physician ofﬁce visits and the second
highest rate of asthma hospitalizations (7, 8).
Asthma in the elderly (AIE) is
underdiagnosed, misdiagnosed, and
frequently undertreated (4, 9). There is
limited information regarding many
aspects (e.g., diagnosis, pathophysiology,
and treatment) of asthma in this age group.
Although there are many clinical and
physiologic features of AIE that are
similar to asthma in younger individuals,
a number of confounding inﬂuences, such
as comorbidities, impaired cognition and
motor skills, and psychosocial effects of
aging, complicate its management. A
workshop by the National Institute on Aging
(NIA) in September 2008 explored the
pathophysiology, recognition, and care of
AIE and identiﬁed a number of knowledge
gaps (10). The American Thoracic Society
(ATS) sponsored a workshop in May 2015
to discuss discoveries about AIE subsequent
to the NIA proceedings to identify future
directions to advance knowledge in the ﬁeld.
Major conclusions from the workshop
included the following:
1. Epidemiology of AIE
d Is common and increasing in
prevalence (7, 11).
d Has high rates of morbidity and
mortality; the most vulnerable older
individuals with asthma are low-
income African-American and
Hispanic women.
2. Structural changes of the aging lungmay
worsen physiologic function in asthma
d With aging, there is loss of elastic
recoil, increased airway remodeling
in the smaller airways, and
increased thickness of the central
airway wall, which may act
synergistically with asthma to
worsen airﬂow obstruction.
3. Immune function and airway
inﬂammation in older patients with
asthma
d Aging itself is associated with altered
immune response and increased
systemic inﬂammation (“inﬂamm-
aging”).
d Differences in airway inﬂammation
between older and younger patients
with asthma are not well
characterized.
d Atopy is common in older patients
with asthma; however, the role of
antigen sensitization and exposure
on disease severity is not deﬁned.
4. Phenotypes of AIE
d Understanding of phenotypes of
AIE is limited and must address
age of asthma onset and overlap
with chronic obstructive pulmonary
disease (COPD), termed asthma–
COPD overlap syndrome (ACOS).
5. Diagnosis of AIE
d There are no speciﬁc physiologic
tests or biomarkers for the
diagnosis and monitoring of AIE.
d Future AIE studies should include
global geriatric assessment tools.
6. Treatment of AIE
d AIE treatment is complex due to
potential reductions in cognitive
and physical function, comorbidities,
polypharmacy, and psychosocial
challenges associated with aging.
d There is limited knowledge on
optimal pharmacological
management strategies and
response to asthma medication in
older adults, largely due to their
exclusion from clinical trials.
d Adverse effects of asthmamedications
are more common in the elderly.
Introduction
Asthma was long considered a childhood
disease. Little attention was given to
asthma in elderly subjects until the Tucson
epidemiologic study of obstructive lung
disease (12–14). This longitudinal study
reported that asthma is common, often
severe, and associated with a high death
rate in people older than 65 years of age.
Subsequent work has demonstrated that
asthma in the elderly (AIE) is generally
poorly understood and, therefore,
underdiagnosed or misdiagnosed and
undertreated (15, 16). An NIA workshop in
September 2008 identiﬁed multiple gaps in
understanding of the disease process of AIE
and its management (10). One major question
raised was whether the pathophysiology
of AIE differs from asthma in younger
patients. An ATS Workshop on The
Evaluation and Management of Asthma
in the Elderly in May 2015 addressed
knowledge gained since the 2008 NIA
conference. In this meeting, a group of
clinicians and basic scientists with expertise
on asthma and aging reviewed the current
state-of-the-art knowledge and identiﬁed
future directions for research. This article
presents the summary of the workshop
ﬁndings on AIE (i.e., deﬁned as asthma in
those older than age 65 yr).
Methods
Clinicians and researchers from various
backgrounds (pulmonary medicine,
allergy and immunology, geriatrics, and
epidemiology) were selected for this
workshop on the basis of their recognized
interests and contributions in the ﬁeld of
AIE (Table 1). Key subtopics pertaining
to AIE were selected by the Chair and
assigned to workshop group members
in alignment with their expertise. The
Program Ofﬁcer for Lung Biology from the
NIA provided guidance for interfacing with
the National Institutes of Health and for
developing strategies for multidisciplinary
research initiatives. Literature searches were
performed with independence regarding
search strategies, inclusion/exclusion criteria,
and subtopic materials for discussion.
Participants presented the current science in
their ﬁeld of expertise relevant to the aging
lung and AIE. Discussion followed each
presentation, and roundtable interactions
helped achieve consensus on current
understanding of AIE, limitations in knowledge,
and future directions. The ﬁndings of the
workshop were written by the participants and
synthesized in the current report. Workshop
participants who had industry relationships
(e.g., industry-funded research) were recused
from writing, editing, and commenting on
related portions of the manuscript.
Results
Update on the Epidemiology of AIE
Asthma imposes a substantial health
burden worldwide, affecting 300 million
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people and ranking 22nd in disability-
adjusted life-years (17). In addition, 250,000
people worldwide die of asthma each year,
due in part to limited access to treatment
(17). Regions with high rates of asthma
include those with increased urbanization
and an aging population (17). Persons
65 years and older are especially
vulnerable to adverse health outcomes
including asthma-related events and
reduced quality of life (QOL), given
age-related reductions in cognitive and
physical function, and increased rates of
comorbid conditions (18–23). In addition,
older Americans often live in urban
environments (24), with higher trafﬁc
pollution predicting poorer asthma-related
QOL (6).
The United States National
Surveillance of Asthma report (7)
shows that across the American lifespan,
those aged 65 years or older had the:
(1) largest increase in the prevalence of
current asthma, (2) highest rate of
asthma-related deaths, (3) second-highest
rate of asthma-based physician ofﬁce
visits and hospitalizations, but
unexpectedly (4) lowest rate of a reported
asthma attack in the previous year or an
emergency department (ED) visit for
asthma. The most vulnerable older
Americans were women, African
Americans, Hispanics, and low-income
groups. Although these observations
may apply to other countries, similar
worldwide epidemiologic investigations
are needed for conﬁrmation (17).
Age-related factors may impact the
epidemiology of AIE, including the
discordant ﬁnding of lower rates of asthma
attacks and asthma-based ED visits
relative to higher rates of asthma deaths,
hospitalizations, and physician ofﬁce visits.
Establishing an asthma diagnosis and
determining asthma-related health care
utilization may be confounded by several
factors: (1) concurrent age-related
increases in comorbidities (e.g., heart
disease, chronic obstructive pulmonary
disease [COPD], etc.), (2) multifactorial
geriatric health conditions (i.e., cognitive
and physical impairments), (3) adverse
effects from polypharmacy, and (4)
psychosocial factors (i.e., lower level of
education, sedentary status, social
isolation, and being homebound) (18–21,
25–27). Furthermore, evaluation of
asthma-based symptoms may be limited
by age-related reductions in awareness of
symptoms (e.g., perception of wheezing)
(28–30) and by the “paradox of well-
being” (31). The latter phenomenon refers
to high levels of life satisfaction in older
persons, which can coexist with lower
health expectations (31), thus increasing
the likelihood that symptoms are missed
or minimized in severity (i.e., delaying
awareness of an asthma attack). This
underrecognition of symptoms may lead
to decreased utilization of ED services,
possibly leading to higher rates of
hospitalization and death.
Update on the Effects of Aging on
Lung Structure and Function as it
Pertains to Asthma
To understand the interaction of asthma
and aging on lung structure and function,
it is critical to ﬁrst review the effects of
aging in the normal lung. It is implicit
that there is biologic heterogeneity of
the aging lung, characterized by great
interindividual variability in chronologic
physiologic change (10). With normal
aging, the collagen ﬁber network that
coils around the alveolar ducts changes,
producing alveolar duct dilation and
homogenous enlargement of alveolar air
spaces (32–36). The alveolar air space
enlargement that occurs in the “senile”
lung differs from emphysema, because
there is no associated inﬂammation or
alveolar wall destruction (34). Alveolar
enlargement decreases alveolar surface
tension and, in turn, decreases elastic
recoil pressure. Degenerative changes of
the spine contribute to kyphosis and, in
combination with increased convexity of
the sternum, increase the anteroposterior
diameter of the chest (33, 36).
Concurrently, chest wall compliance
decreases due to the spinal changes and to
stiffening of the rib cage and reduced
thickness of the parietal muscles (33–35,
37, 38). Respiratory muscle strength
deteriorates due to decreased curvature of
the diaphragm, sarcopenia (i.e., loss of
muscle mass and function), and inadequate
nutrition (32–34, 36–39).
Age-related alterations in lung
structure impact physiologic function
(32–39). The reduction in static elastic
recoil pressure decreases expiratory ﬂow
(i.e., FEV1). In healthy nonsmokers, there is
an z30-ml decline in FEV1 yearly starting
after age 30 years (32, 35, 38), with an
accelerated decline in both FEV1 and FVC
between age 65 and 93 years (40). The
FEV1/FVC ratio also declines with aging
(34), producing a more “obstructive” ﬂow
volume loop (39). Residual volume (RV)
increases by about 50% between ages 20
and 70 years as a result of early airway
closure secondary to reduced lung recoil
combined with reduction in chest wall
compliance and respiratory muscle strength
(34, 35, 38, 39). By age 65 years, closing
volume approaches FRC, so that airways
close even during tidal breathing (34, 39).
Table 1. Methodology
Methods Checklist Yes No
Panel assembly
Included experts from relevant clinical and nonclinical ﬁelds x
Included individuals who represented patients and society at large x
Included methodologist with appropriate expertise (documented
expertise in development of conducting systematic reviews to
identify the evidence base and development of evidence-based
recommendations)
x
Literature review
Performed in collaboration with a librarian x
Searched multiple electronic databases x
Reviewed reference list of retrieved article x
Evidence synthesis
Applied preselected inclusion and exclusion criteria x
Evaluated included articles for sources bias x
Explicitly summarized beneﬁts and harms x
Used PRISMA1 to report systematic review x
Used GRADE to describe quality of evidence x
Generation of recommendations x
Used GRADE to rate the strength of recommendations x
Definition of abbreviations: GRADE =Grades of Recommendation Assessment, Development, and
Evaluation; PRISMA1 = Preferred Reporting Items for Systematic Reviews and Metaanalyses 1.
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This results in ventilation–perfusion
mismatch and widening of the alveolar–
arterial gradient. FRC also increases with
aging, whereas total lung capacity remains
relatively unchanged, because the increased
RV is counterbalanced by the decreased
vital capacity. Diaphragmatic strength in a
76-year-old is about 25% lower than in a
20- to 30-year-old (35), and inspiratory and
expiratory respiratory muscle strength
steadily declines between ages 65 to older
than 85 years in both sexes (39). The
decreased airway caliber in the elderly that
results from these mechanical factors may
enhance the consequences of smooth
muscle shortening after inhalation of a
bronchoconstrictor stimulus, contributing
to increased airway hyperresponsiveness
(AHR) (41) with aging.
In elderly patients with asthma,
pathologic changes of asthma may synergize
with those of normal aging to affect lung
structure and function (Figure 1). Loss of
elastic recoil is reported in chronic asthma
in varying age groups (42, 43). This may
contribute to airﬂow reduction independent
of airway remodeling, a characteristic
feature of asthma in patients of all ages.
Studies of small and large airway wall
area and thickness in older versus
younger individuals with asthma have
shown conﬂicting results by computed
tomography (CT) scans and autopsy
assessments (44, 45). It is likely that aging
alone does not lead to airway remodeling;
however, longer duration of asthma may
lead to increased airway narrowing due to
progressive remodeling and increase in
airway smooth muscle volume (45). Thus,
factors attributable to asthma alone,
combined with those due to normal aging,
may account for the accelerated decline in
FEV1 in asthma noted longitudinally in
some large population studies (46, 47). The
impact of age of asthma onset and of
disease duration on airway function in the
elderly requires further study.
Update on the Effects of Aging on
Immune Function and Airway
Inﬂammation
With advanced age, there are alterations in
both innate and adaptive immune responses
termed “immunosenescence” (Table 2).
In addition, aging is associated with
low-grade, chronic, systemic inﬂammation,
referred to as “inﬂamm-aging,” characterized
by increased IL-1b, IL-6, and tumor necrosis
factor–a (48). Effects of immunosenescence
and inﬂamm-aging on airway inﬂammation
and its regulation in older individuals with
asthma are not well established. However,
there are some studies that have provided
some insight.
Eosinophils from aged subjects may
have some decreased effector functions,
but data on their role in AHR are conﬂicting.
The development of AHR later in life was
associated with elevated peripheral blood
eosinophil counts in men (mean age, 60 yr)
enrolled in the Normative Aging Study (49).
However, peripheral eosinophils from
subjects with asthma (55–80 yr) exhibited
decreased degranulation in response to IL-5
stimulation and a trend for decreased
superoxide production when compared
with cells from patients 20 to 40 years of
age (50), whereas there was no difference
in eosinophil leukotriene C4 production
(51). In a mouse model of asthma,
although antigen-sensitized and airway-
challenged aged mice developed greater
bronchoalveolar ﬂuid eosinophilia than
younger mice, AHR was lower in the
former, suggesting that increased airway
eosinophilia was not correlated with AHR
(52). Taken together, these studies suggest
that although age-associated changes in
eosinophils exist, the clinical implications
of these changes and their relationship to
asthma phenotypes in older patients
remain unclear.
The number of airway neutrophils
increases in older individuals without
airway disease (53–55), and peripheral
neutrophils have increased primary granule
release and neutrophil elastase activity, which
could lead to increased tissue damage (56).
Older compared with younger patients with
asthma have increased sputum neutrophils,
but the impact of inﬂamm-aging on this
increase has not been addressed (44, 50, 57,
58). Airway neutrophilia in older patients
with asthma corresponds to increased levels
of sputum neutrophil mediators, including
matrix metallopeptidase-9, neutrophil
elastase, and IL-8 (58), as well as increased
systemic inﬂammation (e.g., C-reactive
protein and IL-6) (59). This resembles
changes seen in a severe asthma phenotype
noted in some younger adults (60). Aged
mouse models of asthma have demonstrated
increased expression of airway IL-8
and cytokines associated with Th17
cells (61, 62). This could contribute to
increased airway neutrophilia. Determining
the type of underlying airway inﬂammation
in older adults with asthma is important,
as neutrophilic asthma is often less
responsive to corticosteroid treatment
(63, 64).
The role of regulatory T cells (Tregs) in
younger patients with asthma, though not
clearly established, most likely suppresses
airway inﬂammation and AHR (65–67).
Peripheral Treg cell numbers are lower in
younger patients with asthma than in
age-matched healthy subjects (68). Another
study reported that older patients with
asthma had decreased peripheral Treg cells
compared with age-matched normal
control subjects (69), but the importance of
Treg cells in AIE has not been widely
investigated. We are unaware of any studies
that directly compare Tregs in older versus
Alveolar space enlargement
Decreased elastic recoil
pressure
Decreased compliance of the
chest wall and spine
Premature airway closure and
increased air trapping
Decreased elastic recoil
pressure
Effects due to asthmaEffects due to aging
Increased airway
inflammation
Increased airway remodeling
Asthma in the Elderly
More severe, difficult to manage asthma
Figure 1. In the elderly patient with asthma, pathologic changes of asthma may synergize with those
of normal aging to affect both lung structure and function. This may potentially lead to more severe
and difficult-to-control disease.
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younger patients with asthma. However,
aged mice fed low-dose antigen before
sensitization (to induce oral tolerance and
increase Treg expression) and challenge
developed suppressed features of asthma,
including decreased bronchoalveolar ﬂuid
total cell count and eosinophils, cytokine
production, and AHR, suggesting that
Tregs maintained function with aging (70).
Telomere shortening is believed to
be associated with normal aging (71).
During replicative senescence, telomere
shortening may signal cell cycle
arrest or apoptosis (72, 73) or release
proinﬂammatory proteins (74). Shortening
of telomere length in peripheral blood
mononuclear cells correlated with increased
asthma severity in a small group of patients
with asthma (aged 25–60 yr) (75). We are
not aware of any study that speciﬁcally
examined telomere shortening in AIE.
Current Understanding of Phenotypes
of AIE
Phenotypes, the outward manifestation
of an individual’s underlying genetics,
have been widely accepted as a way to
characterize patients with asthma (76–81)
and include clinical, physiologic,
inﬂammatory, and molecular features.
Stratiﬁcation of asthma subtypes by
phenotype and endotype (i.e., speciﬁc
biologic mechanisms) represents the
cutting edge for advancing asthma
treatment. Despite the signiﬁcant health
burden of AIE, we are aware of only one
study exclusively characterizing this
population. Park and colleagues (82)
evaluated 872 patients older than 65 years
of age using cluster analysis to segregate
them into groups with common features
and to assess the risk of asthma
exacerbation in each cluster. A key ﬁnding
from the study was that the cluster with
the longest duration of asthma was more at
risk for acute exacerbation than clusters
with more recent asthma onset and more
normal lung function. Long duration of
asthma and smoking (two distinct clusters)
were associated with accelerated lung
function decline. Although other
investigators, including those from the
Severe Asthma Research Program (76),
have used a similar analytic approach and
have identiﬁed patients with “late-onset
asthma” (LOA), very few of the individuals
included exceeded age 65 years. In one
study (83), patients with “longstanding
asthma” (LSA) reportedly had more atopy
than those with “late-onset disease,” but
the latter category was not limited to
elderly subjects. Others have found that
staphylococcal enterotoxin might be a risk
factor for LOA that may, in some cases, be
nonatopic (32, 84). One “simplistic”
approach to phenotyping elderly asthma
would be to separately evaluate those with
LSA, LOA, and ACOS (85). This may be
challenging because of lack of uniform
deﬁnitions of LSA and LOA as well as
uncertainty about the exact deﬁnition,
prevalence, and overall signiﬁcance of ACOS
(86). Distinguishing patients with ACOS is
important, because they experience more
frequent exacerbations and poorer QOL
(86). AIE displays many of the hallmarks of
COPD (87), and patients with LOA are often
misdiagnosed with COPD or other diseases,
such as congestive heart failure (85).
There are no biomarkers that deﬁnitively
distinguish elderly from younger patients
with asthma, although sputum cellularity is
generally more neutrophilic in AIE. Thus,
current methodologies to phenotype AIE are
insufﬁcient. In addition, several cohort
studies have demonstrated that over long
follow up, it is not uncommon for patients
to change from one cluster designation to
another (88–91). Investigations dedicated to
phenotypic and endotypic characterization
of AIE are therefore needed to facilitate
diagnosis and treatment.
Physiologic Tests and Biomarkers in
the Diagnosis and Management of
Elderly Patients with Asthma
Many of the same tests used in younger
patients with asthma are useful to
characterize AIE (Table 3). Spirometry
and airway reactivity measurements are
ﬁrst-line methods for diagnosing and
monitoring AIE, as in younger patients,
although the nature of the airway disease
may differ in the elderly. Many studies
show lower FEV1 and more severe airﬂow
limitation in older patients with asthma
(44, 92, 93). Bronchoprovocation testing
can detect airway reactivity in older as in
younger patients (44, 94), and older
patients tend to have more peripheral
airway closure during bronchoconstriction
(measured by the reduction in FVC) than
younger patients with asthma (92).
When evaluating spirometry in older
patients, age-adjusted values are essential,
particularly when interpreting the
FEV1/FVC ratio, to avoid overdiagnosing
respiratory impairment (95). Although
predicted values for spirometry are
available for the elderly (96), data for
nonwhite individuals and for those older
than 75 years are sparse. An important
limitation of spirometry, and thus also
of standard bronchoprovocation tests in
the elderly, is that these involve effort-
dependent maneuvers. Although studies
(97, 98) have shown that 80% or more of
older persons can achieve ATS-acceptable
spirometry, this may be hard for some frail
Table 2. Features of immunosenescence: potential impact on asthma in the elderly
Type of
Immunity
Cell Type Observations
Innate Eosinophil ↑ Peripheral eosinophilia and AHR in men
(Normative Aging Study)
↓ Degranulation of peripheral eosinophils in older
patients with asthma
Neutrophil ↑ BALF neutrophils and neutrophil elastase
activity with aging in patients without asthma
↑ Sputum neutrophils in older versus younger
patients with asthma
↑ Levels of sputum neutrophil mediators in older
patients with asthma (e.g., IL-8, MMP-9,
neutrophil elastase)
Adaptive cellular
immunity
Tregs ↓ Peripheral Tregs in older patients with asthma
versus aged control subjects
T cells ↑ Proinﬂammatory cytokines with aging
(inﬂamm-aging)
Adaptive humoral
immunity
Humoral immunity ↓ Antibody response to vaccines
Definition of abbreviations: AHR = airway hyperresponsiveness; BALF = bronchoalveolar lavage fluid;
MMP =matrix metallopeptidase; Tregs = regulatory T cells.
AMERICAN THORACIC SOCIETY DOCUMENTS
2068 AnnalsATS Volume 13 Number 11| November 2016
elderly patients (99–101). The FEV1/FEV6
may be a more easily obtained surrogate for
FEV1/FVC in such individuals (102, 103).
Bronchoprovocation challenges may be
contraindicated in some elderly patients
due to low baseline lung function and
cardiac comorbidities.
Forced oscillation may be useful to
follow older patients with asthma, as it is
provides an effort-independent evaluation
of respiratory system mechanics. Forced
oscillation measures changes in lung
impedance, and data obtained at different
frequencies of applied pressure provide
insight into abnormalities in different lung
regions. Inoue and colleagues found that
elderly patients with asthma had signiﬁcantly
greater resistance of the respiratory system
at 5 Hz, signiﬁcantly greater frequency
dependence of resistance (resistance at 5–20
Hz), and more negative reactance at 5 Hz
than younger patients with asthma (44).
These observations suggest an abnormality
particularly in the lung periphery, perhaps
reﬂective of increased heterogeneity or
enhanced airway closure during quiet
breathing in elderly patients with asthma.
Imaging may have utility in evaluating
AIE. Chest CT is a noninvasive modality
used to assess lung structure, and
measurements at different lung volumes can
be used to make inferences about lung
function. Chest CT in elderly patients with
asthma shows increased wall thickness and
increased air trapping compared with younger
patients with asthma (44). Xenon ventilation
CT in the elderly shows that dyspnea severity
correlates with xenon gas–measured air
trapping, and decreases in gas trapping
correlate with improvements in FEV1.
However, these techniques are limited by the
complexity of the measurements and the
need for specialized imaging and analysis
algorithms not readily available in clinical
practice. The expense and risks of radiation
exposure also obviate CT use.
Exhaled nitric oxide (eNO) is a
biomarker in younger patients with
asthma. Bozek and colleagues found slightly
higher eNO levels in very elderly patients
with asthma (>80 yr) than in a younger
cohort of patients with asthma (18–30 yr)
(104). Other studies report similar levels in
older and younger patients with asthma
(44). Porsbjerg and colleagues found that
eNO levels correlated with airway reactivity
in the elderly (105); this has been
demonstrated in younger individuals as well
(106, 107). Overall, these studies suggest that
eNO likely has similar diagnostic and
monitoring capabilities in both older and
younger patients with asthma.
Update on Strategies to Manage the
Elderly Patient with Asthma
Current evidence-based guidelines for asthma
(86, 108) are derived from studies on
younger individuals, as older patients are
frequently excluded from clinical trials (109).
Only a few reports have addressed the
management of the elderly population with
asthma (10, 110). It is widely accepted that
asthma is often undertreated in older
patients (111–113), likely due to multiple
factors (Table 3), including incomplete
understanding of pathophysiology and most
appropriate age-related therapy, decreased
asthma self-management with aging,
misdiagnosis of AIE, poor access to health
care, comorbidities, medication costs, fear
of corticosteroid use, and poor medication
delivery technique (114–117). The
appropriate management of any chronic
disease in the elderly, including asthma,
should include multidimensional
assessment (MDA) of physical,
psychological, cognitive, and social factors
that may impact successful treatment.
Nonpharmacological management
strategies. Optimal asthma management for
all patients incorporates avoidance of
known asthma triggers. Elderly patients
may have allergy-triggered asthma, although
the role of allergen sensitization in the
Table 3. Diagnostic and treatment comparison of elderly and younger patients with asthma
Test/Characteristic Elderly Young
Spirometry May be less useful in frail patients; reference
standards not widely available
Generally useful tool to assess asthma severity
Bronchodilator responsiveness May be less pronounced Variable but generally greater
eNO May be useful May be useful
Methacholine challenge Less often used because of more frequent
contraindications (e.g., cardiovascular disease)
Useful; overall fewer contraindications
Atopy Less common Common
Comorbidities COPD, heart disease more common Allergic rhinitis more common
Phenotypes Limited knowledge, but late-onset asthma,
long-standing asthma, and ACOS described
Multiple phenotypes described
Sputum cellularity Generally more neutrophilic Generally more eosinophilic
Therapy No age-speciﬁc guidelines Guideline-speciﬁc regimens in place that
address the needs of most patientsOptimal regimen unknown
More susceptible to adverse effects due to
comorbidities, drug-to-drug interactions, and
polypharmacy
Inability to use certain inhalers due to lack of
dexterity and reduced inspiratory ﬂow
Definition of abbreviations: ACOS = asthma–COPD overlap syndrome; COPD = chronic obstructive pulmonary disease; eNO = exhaled nitric oxide.
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Table 4. Progress of understanding of asthma in the elderly: limitations and future directions
Topic Limitation Advances Since NIA
Workshop
ATS Workshop Recommendations
for Future Directions
Epidemiology Absence of age-speciﬁc asthma
guidelines for older patients
resulting in under- and misdiagnosis
Not accomplished Develop geriatric-speciﬁc guidelines
and geriatric- speciﬁc survey
instruments for the diagnosis of
asthma. Develop a more precise
deﬁnition of AIE.
Distinguishing health care utilization
records to identify care of asthma
vs. other comorbid conditions
Develop a survey instrument to better
capture health care utilization for
AIE.
Effect of aging and
asthma on lung
structure and
function
Incomplete understanding of
structural and functional changes in
aging plus asthma vs. aging or
asthma alone
Studies using HRCT scans
of the lung and forced
oscillation testing
Deﬁne normal structural and
functional age- related changes in
the lung (from the cellular to whole-
organ level).
Establish interval imaging of cohorts
of aging individuals to better
understand structural changes in
the lung.
Effect of aging and
AIE on immune
function
Confounding effects of changes in
immune function and inﬂammation
with aging (i.e., inﬂamm-aging).
Additional data on neutrophilic
inﬂammation in AIE
Investigate systemic and lung-speciﬁc
inﬂammatory changes in normal
aging and in aging plus asthma.
Lack of understanding of potential
differences in airway inﬂammation
between older and younger patients
with asthma
Deﬁne the roles of allergen
sensitization and exposure in onset,
progression, and exacerbation of
AIE.
Unclear role of allergen sensitization
and exposure in older patients with
asthma
Appropriate
models for
studying AIE
Difﬁculty obtaining lung tissue and
BALF from older patients
Some new animal model
data on neutrophilic
inﬂammation in AIE
Develop novel allergic and nonallergic
models of asthma, reﬂecting altered
immune cell and cytokine milieu of
the aging lung.
Translation of aged animal studies to
human studies.
Establish biobanks of lung tissue,
sputum, blood, and other samples
from older subjects with and without
asthma.
Asthma
phenotypes
Lack of uniform deﬁnitions and
incomplete characterization of
longstanding versus late-onset AIE
Generally not accomplished.
Staphylococcal enterotoxin
has been identiﬁed as a
potential risk factor for late-
onset asthma.
Design studies in older patients with
asthma of different ages of onset,
incorporating clinical/historical (e.g.,
tobacco use), physiology, imaging,
indices of airway inﬂammation,
molecular biomarkers, and
response to treatment in order to
characterize phenotypes and
endotypes in this population.
Incomplete understanding of the
ACOS
Although ACOS is not
completely understood, the
term was ﬁrst proposed after
the NIA workshop.
Reach consensus deﬁnition on late-
onset asthma.
Physiologic tests
and biomarkers
in AIE
Confounding effects of aging on
physiologic testing on AIE (i.e.,
comorbidities, decreased
respiratory muscle strength,
cognitive impairment)
Useful references standards for
individuals up to age 95 yr
were published in 2012, after
the NIA workshop. However,
data for nonwhite individuals
and for individuals .75 yr of
age are still lacking.
Establish age-appropriate reference
standards for better interpretation of
lung function in the elderly,
particularly for nonwhite individuals
and those of extreme age.
Develop more age-appropriate (i.e.,
effort independent) physiologic
tests to assess AIE.
Investigate the role of currently
available biomarkers in older patients
and identify novel biomarkers to
increase insight into AIE.
(Continued )
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population is less well deﬁned than in
younger patients. Detecting and managing
comorbidities that may exacerbate asthma
are essential to optimize asthma control.
Although inﬂuenza vaccination is
recommended for all patients with asthma
(118), it is underutilized in the elderly
patient with asthma (119). Furthermore,
the immune response to the vaccine
may wane with aging, especially
in patients on high-dose inhaled
corticosteroids (120–122). The long-
term beneﬁt of pulmonary rehabilitation
in elderly asthma, although described
in few published reports, is unknown
(123–126).
Asthma education is important in
managing asthma but may be more difﬁcult
in older populations due to physical and
cognitive function decline. Unfortunately,
asthma education in elderly patients is
poorly implemented (127). An MDA to
asthma care in older patients has been
shown to identify additional signiﬁcant
clinical issues compared with a diagnosis-
centered approach (128). The MDA
should include: (1) standardized
evaluation of comorbidities and
screening for frailty and psychosocial
impediments to care using geriatric-
speciﬁc tools, (2) assessment of barriers
to adherence to inhaled therapy,
(3) individualization of treatment
incorporating age- and disease-speciﬁc
factors, and (4) multiple points of care
and assessment including social workers,
pharmacists, nurses, certiﬁed asthma
educators, and physicians.
Pharmacological management
strategies. Current pharmacological
management of AIE is based on guidelines
developed for younger patients with asthma
with Th2-high or eosinophilic airway
inﬂammation. Studies have shown that
Th2 immune deviation may not be
generalizable to all patients with asthma,
particularly the elderly (58, 63, 129).
Limited inclusion of older patients in
clinical trials and alterations in medication
pharmacodynamics and pharmacokinetics
associated with aging impedes conclusions
on optimal asthma management in this
population. Traditional lung function
measurements to evaluate asthma
medications in clinical trials may be less
useful in the elderly due to increased
prevalence of irreversible obstruction.
Outcomes that are symptom-driven may be
more effective (130, 131). Furthermore,
careful monitoring of inhaler technique
(due to decreased muscle strength and loss
of coordination), medication adherence,
and potential adverse reactions to asthma
medications are essential (130, 132–134).
Rescue medications. Although b2-
receptor responsiveness and afﬁnity may
decline with age, this has not been consistently
established (135, 136). However, elderly
patients may be more sensitive to adverse
effects of b2-agonists, particularly those with
unstable cardiovascular disorders (137, 138).
Animal models suggest that parasympathetic
activity decreases with aging due to reduced
receptor numbers or postreceptor coupling,
but relatively little is known about the effect of
aging on anticholinergic responses in humans.
Short-acting anticholinergic medications
may be useful bronchodilators in the elderly
and do not have the cardiac side effects
of b2-agonists. Although more likely with
oral agents, cognitive impairment, falls,
symptomatic urinary outlet obstruction, and
closed-angle glaucoma are potential risks of
inhaled anticholinergics and should be used
with caution (139).
Controller therapies. Inhaled
corticosteroids (ICS) constitute the
cornerstone of chronic asthma
management, yet they are underutilized in
elderly patients (112, 140, 141). ICS use
reduces hospital admissions and mortality
in this population (142). However,
corticosteroids may be less effective in older
Table 4. (Continued )
Topic Limitation Advances Since NIA
Workshop
ATS Workshop Recommendations
for Future Directions
Management
strategies for
AIE
Complexity of management of AIE due
to comorbidities, polypharmacy,
medication adverse effects, and
psychosocial factors
Not accomplished despite
increased awareness of the
complexity of AIE
Develop speciﬁc guidelines for
managing AIE, incorporating a
multidisciplinary approach.
Lack of inclusion of older patients in
clinical trials for new asthma
therapies
Enroll elderly patients in clinical trials
to better understand age-speciﬁc
treatment response and safety
factors.
Potential age-related altered response
to existing asthma therapies
(e.g., ICS)
Explore novel routes of medication
delivery (e.g., inhaled delivery
devices not dependent on
technique or inspiratory ﬂow,
transdermal, etc.)
Incorporation of
geriatric care
into asthma care
Common geriatric health issues
(e.g., impaired cognition, reduced
strength including reduced lung
function, and frailty) may limit use
of certain therapies.
Not accomplished, although
emphasized more speciﬁcally
in the current report than in
the NIA proceedings
Develop studies incorporating
comorbidities in asthma treatment
to assess the effect of multifactorial
geriatric health conditions on the
clinical trajectory of asthma in older
persons.
Explore role of pulmonary
rehabilitation in AIE, as patients
commonly suffer from physical
dysfunction.
Definition of abbreviations: ACOS = asthma–COPD overlap syndrome; AIE = asthma in the elderly; ATS = American Thoracic Society; BALF =
bronchoalveolar lavage fluid; HRCT = high-resolution computed tomography; ICS = inhaled corticosteroids; NIA = National Institute on Aging.
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patients with asthma with predominantly
neutrophilic inﬂammation; this needs
further study. Older patients receiving
higher-dose ICS should be monitored
closely for potential decreased bone mineral
density, increased fracture risk, and
cataracts (143, 144). The safety of long-
acting b-agonist use in older patients,
particular those with underlying
cardiovascular disease, has been most
studied in COPD, and results are
inconsistent. Some studies suggest that
when used, especially as monotherapy,
there is increased risk of cardiovascular
events (145, 146), whereas other studies
have not shown this (147, 148). Studies
speciﬁcally focused on the safety of this
class of drugs in elderly patients with
asthma are lacking; however, the black box
warning for use of long-acting b-agonist
as monotherapy applies to all patients
with asthma. Long-acting muscarinic
antagonists have been shown to be
efﬁcacious as add-on therapy in patients
with asthma up to age 75 years old (149)
and may be especially helpful in patients
with concomitant COPD (ACOS).
A few studies have reported that
leukotriene modifying agents may beneﬁt
AIE (131, 150). Although signiﬁcant
improvement in asthma indices was
observed in older age groups, it was less
pronounced than in younger patients with
asthma (131) and in older patients treated
with ICS (150). Some older patients
with asthma have demonstrated clinical
improvement after treatment with anti-IgE
therapy (151, 152). Speciﬁc immunotherapy
has also been effective in older patients
and should be considered, but risks and
beneﬁts must be weighed carefully (153, 154).
Comorbidities That Inﬂuence Disease
Severity, Diagnosis, and Management
of AIE
Comorbidities in asthma worsen disease
severity and QOL in all individuals (155),
but more likely to a greater degree in older
patients (156, 157). Concomitant medical
conditions are more common in older
patients (158). Some comorbidities of older
patients with asthma that typically differ
from those of younger patients include
atrial ﬁbrillation (159), congestive
heart failure (157), and COPD (15).
Distinguishing AIE from COPD (15) in older
adults is difﬁcult, and some older patients may
have components of both diseases, or ACOS
(160). The prevalence of bronchiectasis
increases with aging (161), and coexistence
with asthma is associated with more severe
asthma (162), more hospitalizations, and
increased risk of chronic respiratory failure
(163). As in younger patients with asthma,
chronic rhinosinusitis in people older than 65
years is strongly associated with the diagnosis
of asthma (84, 164, 165), in particular
when associated with IgE sensitization to
staphylococcal enterotoxin (84). Obesity, often
prevalent in the elderly, is associated with poor
asthma control and asthma exacerbations
(166). Gastroesophageal reﬂux disease
increases with age (167), likely due to age-
associated reductions in lower esophageal
sphincter pressure, and this may contribute to
asthma exacerbations (168). Cognitive
impairment and change of mood (depression
and/or anxiety) are also common in geriatric
patients, decrease QOL (169), and negatively
inﬂuence adherence to asthma treatment (169,
170). Most importantly, they have been shown
to be independent correlates of mortality in
AIE (137). Sleep disorders are more prevalent
in elderly patients with asthma than in age-
matched control subjects (171) and in young
patients with asthma (172) and have been
associated with low QOL (171, 172).
Comorbidities may interact with
asthma therapy by modifying the
pharmacokinetics and pharmacodynamics
of asthma medications. Renal or hepatic
diseases, for example, can impair the
absorption, distribution, metabolism, and
excretion of drugs, thus increasing risk
of side effects (173). Even patients with
normal serum creatinine can have reduced
glomerular ﬁltration rates, so that the risk
of side effects related to renal dysfunction
should not be underestimated (174).
Furthermore, some medications used to
treat comorbidities may worsen asthma
(e.g., b-blockers, aspirin, nonsteroidal
antiinﬂammatory drugs, cholinergic agents,
etc.). Comorbidities are also invariably
associated with polypharmacotherapy, an
important risk factor for adverse drug
reactions in the elderly. Aging, per se, is also
responsible for pharmacokinetic changes
(175), which should be accounted for when
developing a pharmacotherapy plan.
Limitations and Future
Directions
Advances in knowledge about AIE have
been hindered by multiple factors (Table 4).
Diagnosing and phenotyping AIE is
confounded by the effects of normal
age-related changes in the lung, by
underreporting of symptoms, and by
comorbidities. In addition, absence of
a precise deﬁnition for AIE, lack of
appropriate models to study the disease,
and failure to include older adults in
clinical trials contribute to gaps in
understanding. Although there has been
some progress since the NIA proceedings,
major research questions remain
unanswered. Recommendations for future
directions were established by consensus of
the current workshop group.
Conclusions
In May 2015, the ATS sponsored a
workshop to evaluate and report on
discoveries about AIE since the NIA
workshop and to identify future directions
to advance knowledge in this ﬁeld. AIE, a
complex entity with poorly understood
phenotypic heterogeneity (including
inﬂammatory proﬁles), is impacted by
comorbidities of advancing age, such as
heart disease, concomitant lung disease
(e.g., COPD), cognitive impairment, and
depression, and also by natural changes of
the aging respiratory and immune systems.
Although asthma in persons aged 65 years
and older has had the largest increase in
prevalence and the highest mortality of any
age group, geriatric-speciﬁc guidelines are
not available for diagnosis and treatment of
AIE. Physiologic tests for elderly patients
with asthma are the same as those used in
younger individuals, and age-appropriate
inﬂammatory biomarkers have not been
identiﬁed. As the population is aging, AIE
will present a greater future management
issue. Therefore, it is imperative that
research efforts focus on characterization of
AIE to enhance diagnostic and treatment
strategies for this vulnerable population. n
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